Transcatheter Mitral Valve Repair in 2026: MitraClip and Beyond
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-05-15 · 9 min read
For high-risk patients with severe mitral regurgitation, percutaneous valve repair now rivals open surgery. See the latest COAPT and EXPAND-G4 data.
Saving Hearts Without Opening Chests
Severe mitral regurgitation (MR) affects 4 million Americans and worsens heart failure. Transcatheter edge-to-edge repair (TEER) clips the leaky valve leaflets together — through a catheter in the femoral vein.
2026 Devices
- MitraClip G4 (Abbott) — most-used worldwide
- PASCAL Precision (Edwards) — independent clasp control
- MitraBridge — early-stage repositionable system
Who Benefits
- Functional MR with reduced ejection fraction (COAPT criteria)
- Degenerative MR in high-surgical-risk patients
- Symptomatic heart failure despite optimal medication
Outcomes (COAPT 5-year)
- 47% reduction in heart failure hospitalizations
- 41% reduction in mortality
- Significant quality-of-life improvement
Recovery
- Hospital stay: 1-2 days
- Return to normal activity: 1-2 weeks
- No sternotomy, no cardiopulmonary bypass
Many TEER patients also have sleep-disordered breathing. Optimizing CPAP or ASV therapy with the right BiPAP machine reduces nocturnal mitral regurgitation and improves long-term outcomes.